Gefitinib in Non Small Cell Lung Cancer

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Costanzo, Raffaele, Piccirillo, Maria Carmela, Sandomenico, Claudia, Carillio, Guido, Montanino, Agnese, Daniele, Gennaro, Giordano, Pasqualina, Bryce, Jane, De Feo, Gianfranco, Di Maio, Massimo, Rocco, Gaetano, Normanno, Nicola, Perrone, Francesco, Morabito, Alessandro
格式: Artigo
語言:Inglês
出版: Hindawi Publishing Corporation 2011
主題:
Review Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3110340/
https://ncbi.nlm.nih.gov/pubmed/21660144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/815269
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍